Foghorn Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Foghorn Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Foghorn Therapeutics Inc. FHTX.OQ reported a quarterly adjusted loss of 10 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -28 cents. The mean expectation of ten analysts for the quarter was for a loss of 26 cents per share. Wall Street expected results to range from -35 cents to -16 cents per share.
Revenue rose 112.7% to $16.07 million from a year ago; analysts expected $6.00 million.
Foghorn Therapeutics Inc.'s reported EPS for the quarter was a loss of 10 cents.
The company reported a quarterly loss of $7.19 million.
Foghorn Therapeutics Inc. shares had held steady so far this quarter and lost 9.6% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 3.4% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Foghorn Therapeutics Inc. is $12.00, about 59.3% above its last closing price of $4.88
This summary was machine generated from LSEG data August 6 at 02:20 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.26 | -0.10 | Beat |
Mar. 31 2026 | -0.30 | -0.29 | Beat |
Dec. 31 2025 | -0.25 | -0.34 | Missed |
Sep. 30 2025 | -0.33 | -0.25 | Beat |